Novel therapeutic strategies for multiple sclerosis targeting autoantibodies against talin.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09333
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurology
• Research Institution: Chiba University
• Principal Investigator: Masahiro Mori 千葉大学, 大学院医学研究院, 准教授 (70345023)
• Co-Investigator(Kenkyū-buntansha): 鵜沢 顕之 千葉大学, 医学部附属病院, 助教 (10533317) ; 日和佐 隆樹 千葉大学, 大学院医学研究院, 准教授 (30260251)
• Research Collaborator: UCHIDA Tomohiko 千葉大学, 大学院医学研究院, 医員 ; MASUDA Hiroki 千葉大学, 大学院医学研究院, 特任助教 ; OHTANI Ryouhei 千葉大学, 大学院医学研究院, 医員 ; LIU Jia 千葉大学, 大学院医学研究院, 大学院生 ; SUGIMOTO Manabu 千葉大学, 大学院医学研究院, 大学院生
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 多発性硬化症 / talin-1 / 自己抗体 / 神経免疫疾患

Outline of Final Research Achievements

We measured titers of antibodies against talin-1(TLN1) identified by SEREX and concentrations of soluble form of TLN1 (sTLN1) in large scale of multiple sclerosis (MS) patients, and normal controls. The results showed both anti-TLN1 antibody titers and sTLN1 were significantly higher in MS patients than in normal controls. In conclusion, novel autoantibodies against TLN1 can be found in sera from some MS patients; the production of serum anti-TLN1 antibody in MS is thought to be caused not by response to elevation of sTLN1.

Free Research Field

神経内科、神経免疫、多発性硬化症